Who are Lenvatinib and Sorafenib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sorafenib Standard Dosing Regimen, Sorafenib Ramp-Up Regimen, Sorafenib (SOR), Sorafenib (SORA), Len-TACE, TACE plus sorafenib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenvatinib-and-sorafenib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lenvatinib and Sorafenib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lenvatinib and Sorafenib (Lenvatinib and Sorafenib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-kinase inhibitor. Area: Oncology.

phase 2 Multi-kinase inhibitor VEGFR, PDGFR, FGFR, and other kinases Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lenvatinib and Sorafenib (Lenvatinib and Sorafenib) — Stephen Chan Lam. Multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lenvatinib and Sorafenib TARGET	Lenvatinib and Sorafenib	Stephen Chan Lam	phase 2	Multi-kinase inhibitor	VEGFR, PDGFR, FGFR, and other kinases
Sorafenib Standard Dosing Regimen	Sorafenib Standard Dosing Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib Ramp-Up Regimen	Sorafenib Ramp-Up Regimen	University of Florida	marketed	Multi-kinase inhibitor	BRAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SOR)	Sorafenib (SOR)	The University of Texas Health Science Center at San Antonio	marketed	Multi-kinase inhibitor; RAF/VEGFR/PDGFR inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β, FLT-3, c-KIT
Sorafenib (SORA)	Sorafenib (SORA)	Nanfang Hospital, Southern Medical University	marketed	Multi-kinase inhibitor	RAF, VEGFR-2, VEGFR-3, PDGFR-β
Len-TACE	Len-TACE	Second Affiliated Hospital of Guangzhou Medical University	phase 3	Multi-kinase inhibitor (combined with transarterial chemoembolization)	FGFR, VEGFR, RET, KIT
TACE plus sorafenib	TACE plus sorafenib	Guangxi Medical University	phase 3	Combination therapy (locoregional procedure + multi-kinase inhibitor)	VEGFR, PDGFR, RAF kinases (sorafenib component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-kinase inhibitor class)

University of Florida · 2 drugs in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class
Stephen Chan Lam · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenvatinib and Sorafenib — Competitive Intelligence Brief. https://druglandscape.com/ci/lenvatinib-and-sorafenib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab